Hervé Affagard
Founder & Chief Executive Officer MaaT Pharma
Seminars
Wednesday 25th June 2025
Roundtable: Advancing Microbiome Therapeutics: Insights from the MTIG and EMIH Collaboration
8:00 am
- How can harmonized regulatory frameworks benefit microbiome therapeutics across different regions, and what specific steps can be taken to achieve this harmonization?
- What innovative strategies can be employed to accelerate the development of microbiome-based therapies through international collaboration, and how can these strategies be effectively implemented?
- How can expanding access to microbiome therapies benefit the economy and healthcare systems, and what measures are necessary to ensure equitable access to these innovative treatments?
Tuesday 24th June 2025
MaaT013: The First Phase 3 Trial for Microbiome Therapy in Hemato-Oncology
9:30 am
- Discussing the ongoing pivotal Phase 3 ARES trial for MaaT013 in patients with acute Graft-versus-Host Disease (GI-aGvHD) and its significance as the first global Phase 3 trial for a microbiome-based therapy in hemato-oncology
- Highlighting the Orphan Drug Designation from both the FDA and EMA, and the positive outcomes from the Data Safety Monitoring Board (DSMB) review.
- Exploring the positive Phase 3 ARES results, evaluating MaaT013’s unprecedented efficacy as a third-line treatment for GI-aGvHD
